Why Equillium, Inc.’s (EQ) Stock Is Down 5.24%
As of Tuesday, August 18, Equillium, Inc.’s EQ share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Commentary & Analysis
Why Equillium, Inc.’s (EQ) Stock Is Up 7.96%
As of Friday, August 14, Equillium, Inc.’s EQ share price has surged by 7.96%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Equillium, Inc.’s (EQ) Stock Is Down 5.94%
As of Tuesday, August 11, Equillium, Inc.’s EQ share price has dipped by 5.94%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Equillium, Inc.’s (EQ) Stock Is Down 5.17%
As of Friday, July 31, Equillium, Inc.’s EQ share price has dipped by 5.17%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Equillium, Inc.’s (EQ) Stock Is Down 7.72%
As of Tuesday, July 28, Equillium, Inc.’s EQ share price has dipped by 7.72%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | EQ | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $143.9 | $286.3 | 24% |
|
| Shares Out (Mil) | 111.8 | 54.2 | 64% |
|
| Institutional Ownership | 79.7% | 92.8% | 49% |
|
| Float (Mil) | 36.8 | 39.7 | 40% |
|
| Beta | 1.81 | 0.94 | 90% |
|
| Avg Daily Volume (000s) | 532 | 534 | 59% |
|
| Price Change (52-week) |
89.2% | 58.7% | 89% |
|
| Growth | EQ | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 5.5% | (10.1%) | 48% |
|
| EPS (5yr) | 23.2% | 16.0% | 73 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.9%) | (15.6%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.051) | ($0.206) | ($0.234) | |
| Month Ago EPS | ($0.051) | ($0.241) | ($0.266) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.051) | ($0.248) | ($0.263) | |
| Year/Year Chg | 21.4% | (47.3%) | (27.1%) | |
| Financials | EQ | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($43) | 25% |
|
| EPS (TTM) | ($0.197) | ($1.400) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $46 | $2 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $91 | $160 | 21% |
|
| Valuation | EQ | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.58 | 2.77 | 59% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | EQ | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (50.7%) | (47.3%) | 11% |
|
| ROE | (59.0%) | (55.0%) | 14% |
|
| Liabilities to Assets | 4.5% | 29.6% | 2% |
|
| F-Score | 2 | 2 | 7% |
|
Equillium, Inc. did not pass any screens on 8/20/2026.
